177 related articles for article (PubMed ID: 36580798)
21. Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment.
Zhou S; Xu Z; Yang B; Guan J; Shan W; Shi Y; Chen X
J Gynecol Oncol; 2021 Jul; 32(4):e57. PubMed ID: 34085795
[TBL] [Abstract][Full Text] [Related]
22. Assessing the prognostic value of PAX2 and PTEN in endometrial carcinogenesis.
Rewcastle E; Varhaugvik AE; Gudlaugsson E; Steinbakk A; Skaland I; van Diermen B; Baak JP; Janssen EAM
Endocr Relat Cancer; 2018 Dec; 25(12):981-991. PubMed ID: 30400021
[TBL] [Abstract][Full Text] [Related]
23. Use of clinicopathological factors to predict prognosis of fertility-sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia.
Zhang X; Zhao X; Wang C; Lu S; Wang Y; He Y; Wang J; Shen D
Oncol Lett; 2023 Feb; 25(2):52. PubMed ID: 36644134
[TBL] [Abstract][Full Text] [Related]
24. YTHDF2 is a novel diagnostic marker of endometrial adenocarcinoma and endometrial atypical hyperplasia/ intraepithelial neoplasia.
Bian PP; Liu SY; Luo QP; Xiong ZT
Pathol Res Pract; 2022 Jun; 234():153919. PubMed ID: 35512522
[TBL] [Abstract][Full Text] [Related]
25. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological characteristics and fertility preserving treatment of atypical polypoid adenomyoma.
Wang Q; Shan W; Yang B; Xue Y; Lou Y; Chen X
Front Oncol; 2024; 14():1386931. PubMed ID: 38863630
[TBL] [Abstract][Full Text] [Related]
27. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
28. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
Raffone A; Catena U; Travaglino A; Masciullo V; Spadola S; Della Corte L; Piermattei A; Insabato L; Zannoni GF; Scambia G; Zullo F; Bifulco G; Fanfani F; Di Spiezio Sardo A
Gynecol Oncol; 2021 Jun; 161(3):795-801. PubMed ID: 33812697
[TBL] [Abstract][Full Text] [Related]
29. Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment.
Raffone A; Travaglino A; Saccone G; Di Maio A; Mollo A; Mascolo M; De Rosa R; De Placido G; Insabato L; Zullo F
Gynecol Endocrinol; 2019 Nov; 35(11):932-937. PubMed ID: 31165649
[No Abstract] [Full Text] [Related]
30. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: Wait or treat!
İşçi Bostancı E; Durmuş Y; Duru Çöteli AS; Kayıkçıoğlu F; Boran N
Turk J Med Sci; 2021 Aug; 51(4):2066-2072. PubMed ID: 34013707
[TBL] [Abstract][Full Text] [Related]
32. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience.
Wang Y; Yu M; Yang JX; Cao DY; Yuan Z; Zhou HM; Zhang Y; Li L; Shen K; Wu H
Int J Clin Oncol; 2019 Jun; 24(6):712-720. PubMed ID: 30746595
[TBL] [Abstract][Full Text] [Related]
33. Fertility-Sparing Management Using Progestin for Young Women with Endometrial Cancer From a Population-Based Study.
Kim SR; van der Zanden C; Ikiz H; Kuzelijevic B; Havelock J; Kwon JS
J Obstet Gynaecol Can; 2018 Mar; 40(3):328-333. PubMed ID: 28986185
[TBL] [Abstract][Full Text] [Related]
34. The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Guan J; Chen XJ
Front Endocrinol (Lausanne); 2022; 13():1041535. PubMed ID: 36387903
[TBL] [Abstract][Full Text] [Related]
35. Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression.
Huang HN; Kuo CW; Lin MC; Mao TL; Kuo KT
Appl Immunohistochem Mol Morphol; 2020 Apr; 28(4):284-289. PubMed ID: 30789355
[TBL] [Abstract][Full Text] [Related]
36. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
Rubatt JM; Slomovitz BM; Burke TW; Broaddus RR
Gynecol Oncol; 2005 Nov; 99(2):472-6. PubMed ID: 16099019
[TBL] [Abstract][Full Text] [Related]
37. Molecular subtyping in endometrial cancer: A promising strategy to guide fertility preservation.
Dagher C; Manning-Geist B; Ellenson LH; Weigelt B; Rios-Doria E; Barry D; Abu-Rustum NR; Leitao MM; Mueller JJ
Gynecol Oncol; 2023 Dec; 179():180-187. PubMed ID: 37992549
[TBL] [Abstract][Full Text] [Related]
38. Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population.
Kang N; Zhang X; Wang Z; Dai Y; Lu S; Su W; Gai F; Zhu C; Shen D; Wang J
Pathol Res Pract; 2024 Feb; 254():155152. PubMed ID: 38277742
[TBL] [Abstract][Full Text] [Related]
39. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
40. Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment.
Peng H; Jiang J; Li L; Hao Z; Lian H; Du H; Wang W
Gynecol Oncol; 2024 Apr; 186():154-160. PubMed ID: 38691985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
